Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Examining SERCA2a Acetylation in the Diseased Human Heart

EF 2019-20

Résumé
"Heart disease is the leading cause of death worldwide. Researchers have discovered that during the development of heart disease, a protein in the heart called SERCA2a becomes damaged. This is a problem because SERCA2a moves calcium within the heart and is responsible for relaxing the heart after each time it beats. Researchers have also discovered that SERCA2a proteins may be influenced by a process called acetylation, where an acetyl group is added to a target protein. In fact, we know that SERCA2a can hold 3 acetyl groups. In some cases, the addition of an acetyl group turns proteins on, while in other cases it turns proteins off. Our most recent research suggests that the acetylation of SERCA2a turns it off. However, we still do not know if the acetylation of SERCA2a directly contributes to the development of heart disease. Therefore, this research project will determine the clinical relevance of SERCA2a acetylation in the diseased human heart. To accomplish this, we will work closely with heart surgeons to collect human heart tissue that is removed and discarded as a normal part of surgery. We will also collect human heart tissue from heart surgery patients with type 2 diabetes to determine if SERCA2a acetylation is worse in this condition, which may explain why people with diabetes tend to develop heart disease more often than people who do not have diabetes. Our work will use experimental techniques such as immunoprecipitation, SERCA activity assays, and Western blotting to examine the effect of SERCA2a acetylation. The information gathered from this research may be used to create new strategies to treat heart disease by altering SERCA2a acetylation. This outcome would be a unique therapy for the diseased human heart."
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
429005
Name
Oldfield Christopher J
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Examining SERCA2a Acetylation in the Diseased Human Heart
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acetylation; Calcium Handling; Cardiomyopathy; Contractile Dysfunction; Heart Disease; Heart Failure; Humans; Post-Translational Modifications; Serca2a; Type 2 Diabetes
Abstract
"Heart disease is the leading cause of death worldwide. Researchers have discovered that during the development of heart disease, a protein in the heart called SERCA2a becomes damaged. This is a problem because SERCA2a moves calcium within the heart and is responsible for relaxing the heart after each time it beats. Researchers have also discovered that SERCA2a proteins may be influenced by a process called acetylation, where an acetyl group is added to a target protein. In fact, we know that SERCA2a can hold 3 acetyl groups. In some cases, the addition of an acetyl group turns proteins on, while in other cases it turns proteins off. Our most recent research suggests that the acetylation of SERCA2a turns it off. However, we still do not know if the acetylation of SERCA2a directly contributes to the development of heart disease. Therefore, this research project will determine the clinical relevance of SERCA2a acetylation in the diseased human heart. To accomplish this, we will work closely with heart surgeons to collect human heart tissue that is removed and discarded as a normal part of surgery. We will also collect human heart tissue from heart surgery patients with type 2 diabetes to determine if SERCA2a acetylation is worse in this condition, which may explain why people with diabetes tend to develop heart disease more often than people who do not have diabetes. Our work will use experimental techniques such as immunoprecipitation, SERCA activity assays, and Western blotting to examine the effect of SERCA2a acetylation. The information gathered from this research may be used to create new strategies to treat heart disease by altering SERCA2a acetylation. This outcome would be a unique therapy for the diseased human heart."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Oldfield, Christopher J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~